OXFORD, England–(BUSINESS WIRE<\/a>)– \nBoth molecules were funded through a 2019 collaboration with Celgene, which was acquired by Bristol Myers Squibb, and each molecule met the criteria for which BMS could exercise its option. Bristol Myers Squibb’s options to the candidates have now lapsed and Exscientia maintains all worldwide rights to both compounds. In 2021, an agreement was signed to expand the collaboration to include additional programmes in oncology and immunology. These programmes are currently in active development.\n<\/p>\n \n\u201cBuilding off of our success with the CDK7, A2A<\/sub> and PKC-theta programmes, these candidates clearly show how our AI-driven precision design platform can solve challenging target profiles in a more efficient way than traditional drug discovery,\u201d said Professor Andrew Hopkins, D.Phil., founder and Chief Executive Officer of Exscientia. \u201cBoth ‘539 and ‘565 met the primary nonclinical design goals for potency, selectivity, dosing and safety. In addition, these molecules also have the potential for meaningful patient selection strategies to optimise clinical design. We are excited about the promise these compounds hold in a broad range of haematologic and solid tumours.\u201d\n<\/p>\n First potent, selective, reversible and brain-penetrant LSD1 inhibitor: <\/b>EXS74539 (‘539)is a differentiated lysine demethylase 1 (LSD1) inhibitor with potential in both haematology and oncology. LSD1 demethylates histones play a critical role in regulating the expression of genes which suppress differentiation and drive the proliferation and survival of a number of tumour types. To date, other LSD1 inhibitors in development have failed to achieve the combination of appropriate pharmacokinetics, good brain penetrance and a reversible mechanism of action. Exscientia’s candidate, ‘539, achieves a design objective of suitable CNS penetration to target brain metastases, which are prevalent in certain cancer subtypes. Additionally, in vivo<\/i> studies of ‘539 have shown favourable activity in small cell lung cancer (SCLC) xenograft models, with dose dependent inhibition of tumour growth. Studies have also shown a favourable absorption, distribution, metabolism, and excretion (ADME) profile, with a shorter predicted human half-life than some LSD1 inhibitors currently in clinical trials. No safety concerns have been observed in preclinical studies conducted to date. Exscientia will present data on the discovery and development of ‘539 at an upcoming scientific conference in the first half of 2023.\n<\/p>\n Potent and selective MALT1 protease inhibitor with potential safety differentiation: <\/b>EXS73565 (‘565) is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) protease inhibitor with potential applications in haematology. MALT1 is a protease crucial for activation of the NF-\u03baB pathway which supports the uncontrolled proliferation of malignant T- and B-cells in haematological cancers. Exscientia\u2019s precision design approach was able to optimise the safety profile for agents targeting MALT1 whilst also generating potency and selectivity. Scaffolds of other MALT1 inhibitors in the clinic significantly inhibit UGT1A1, an enzyme involved in the metabolism of bilirubin, often leading to dose-limiting toxicities in the clinic. In vivo<\/i> studies of ‘565 have shown anti-tumour activity in mouse models and favourable pharmacokinetics both as monotherapy and in combination with ibrutinib. Toxicology studies have shown that \u2018565 has an acceptable therapeutic index, with the ability to maintain high levels of potency, selectivity and safety benchmarks while avoiding meaningful inhibition of UGT1A1, which can lead to hyperbilirubinemia.\n<\/p>\n \n\u201cWith three existing clinical programmes already in the pipeline, we feel very confident we will meet our goal of four clinical stage compounds in 2024,\u201d said Prof. Hopkins. \u201cOur vision is to change the way drug design, discovery and development is done, as we have shown in our first eight drug candidates. Over the course of 2023, we expect to provide more details on these programmes as well as on our broader internal and partnered pipeline.\u201d\n<\/p>\n About Exscientia<\/b><\/p>\n \nExscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.\n<\/p>\n \nVisit us at https:\/\/www.exscientia.ai<\/a> or follow us on Twitter @exscientiaAI<\/a>.\n<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nThis press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the progress of discovery and development of candidate molecules, and the timing and progress of, and data reported from, clinical trials of Exscientia\u2019s product candidates, and Exscientia\u2019s expectations regarding the potential benefit of any of its product candidates or number of clinical stage candidates Exscientia expects to have by 2024. Any statement describing Exscientia\u2019s goals, plans, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the impact that macroeconomic conditions and geopolitical events could have on the Company\u2019s business; the initiation, scope and progress of Exscientia\u2019s and its partners\u2019 planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia\u2019s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https:\/\/www.sec.gov\/<\/a>), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia\u2019s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia\u2019s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230314005450\/en\/<\/a><\/span><\/p>\n Investor Relations: Media: KEYWORDS:<\/b> Europe United States United Kingdom North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Oncology Health Artificial Intelligence Health Technology Technology Clinical Trials<\/p>\n
\nExscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (\u2018539), an LSD1 inhibitor, and EXS73565 (‘565), a MALT1 protease inhibitor. These compounds have been precision designed to improve the potential for patient benefit and solve complex design issues that may limit the probability of success of other compounds in development. IND-enabling studies are underway and the Company expects to provide an update on clinical development plans leveraging Exscientia’s personalised medicine platform in the second half of 2023.\n<\/p>\n<\/p>\n
\n<\/b>
Sara Sherman
\n
investors@exscientia.ai<\/a><\/p>\n
\n<\/b>
Oliver Stohlmann
\n
media@exscientia.ai<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230314005450\/en\/1737617\/3\/Exscientia_Logo_for_BW.jpg\"){kind=logo}
<\/td>\n<\/tr>\n